IFNG and cancer: All of these PBMCs from cancer patients, but not from those of any HDs, also produced higher levels of IFN-γ production (>100 pg ml−1) in response to OSC20 cells (HLA-B46+HSC70+) but not in response to Kuma-1 cells (HLA-B46−HSC70+) (Figure 2A).